Amber Bio

About Amber Bio

Amber Bio is developing a novel RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. This approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine.

```xml <problem> Current genetic medicine approaches often require developing separate therapies for each mutation within a patient population. This approach is not scalable and leaves many patients with previously undruggable conditions. </problem> <solution> Amber Bio is developing an RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. Their approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine. The company's platform is designed to be safe and reversible, allowing for larger edits than current gene editing technologies. By studying biological systems and applying biological design principles, Amber Bio aims to create gene therapies that are safe, easy, precise, and affordable. </solution> <features> - RNA writing platform capable of editing thousands of diverse mutations across patients with a single product - Multi-kilobase edits for addressing previously undruggable conditions - Designed for safe and reversible gene editing - Biologically inspired approach leveraging sophisticated biological systems - Focus on creating gene therapies that are safe, easy, precise, and affordable </features> <target_audience> Amber Bio's primary target audience includes patients with genetic diseases and the biotechnology companies developing genetic medicines. </target_audience> ```

What does Amber Bio do?

Amber Bio is developing a novel RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. This approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine.

Where is Amber Bio located?

Amber Bio is based in San Francisco, United States.

When was Amber Bio founded?

Amber Bio was founded in 2021.

How much funding has Amber Bio raised?

Amber Bio has raised 26000000.

Location
San Francisco, United States
Founded
2021
Funding
26000000
Employees
20 employees
Major Investors
Playground Global, Andreessen Horowitz

Find Investable Startups and Competitors

Search thousands of startups using natural language

Amber Bio

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

Amber Bio is developing a novel RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. This approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine.

amber.bio5K+
cb
Crunchbase
Founded 2021San Francisco, United States

Funding

$

Estimated Funding

$20M+

Major Investors

Playground Global, Andreessen Horowitz

Team (20+)

No team information available.

Company Description

Problem

Current genetic medicine approaches often require developing separate therapies for each mutation within a patient population. This approach is not scalable and leaves many patients with previously undruggable conditions.

Solution

Amber Bio is developing an RNA writing platform that enables multi-kilobase gene edits to target diverse mutations in patient populations with previously undruggable conditions. Their approach eliminates the need for separate therapies for each mutation, providing a scalable solution for genetic medicine. The company's platform is designed to be safe and reversible, allowing for larger edits than current gene editing technologies. By studying biological systems and applying biological design principles, Amber Bio aims to create gene therapies that are safe, easy, precise, and affordable.

Features

RNA writing platform capable of editing thousands of diverse mutations across patients with a single product

Multi-kilobase edits for addressing previously undruggable conditions

Designed for safe and reversible gene editing

Biologically inspired approach leveraging sophisticated biological systems

Focus on creating gene therapies that are safe, easy, precise, and affordable

Target Audience

Amber Bio's primary target audience includes patients with genetic diseases and the biotechnology companies developing genetic medicines.

Want to add first party data to your startup here or get your entry removed? You can edit it yourself by logging in with your company domain.